LRP2 and chronic kidney disease: Moreover, in LS patients’ insulin signaling could be partially inhibited, affecting other processes including the stimulation of megalin expression under chronic kidney disease (Hosojima et al., 2009; Bryniarski et al., 2018) and the insulin-mediated surface expression of GLUT4, a trafficking response that is inhibited by GSK3ß (Duan X et al., 2021).